CytRx presents aldoxorubicin Phase 2b trial data
CytRx announced that Phase 2b trial data comparing first-line treatment with aldoxorubicin has been selected for oral presentation at the 2014 American Society for Clinical Oncology Annual Meeting. Aldoxorubicin is currently being studied in a pivotal, global Phase 3 clinical trial evaluating the efficacy and safety of aldoxorubicin as a second-line treatment for patients with STS under a Special Protocol Assessment with the FDA. CytRx is also conducting two Phase 2 clinical trials evaluating aldoxorubicin in patients with late-stage glioblastoma and HIV-related Kaposi’s sarcoma.
